A control study of modified docetaxel regimens versus 3-week docetaxel regimens in the treatment of metastatic castration-resistant prostate cancer with poor chemotherapy tolerance

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041337

Enrollment

Unknown

Registered

2020-12-23

Start date

2020-01-01

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic castration-resistant prostate cancer

Interventions

the modified DP regimen (modified group):Docetaxel 35mg/? d1, 30mg/? d8 intravenous infusion + prednisone 5mg orally bid d1-21/21 days as a cycle, after 1 cycle of chemotherapy, adjust the dose of doc

the standard DP regimen (standard group):Docetaxel 65mg/? d1 intravenous infusion + prednisone 5mg orally bid d1-21/21 days as a cycle

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Subjects over 18 years old; 2. Male; 3. Patients meeting the criteria of metastatic castration resistant prostate cancer: 4. Before chemotherapy, the patients with grade 3 or more toxic and side effects were assessed as medium or high risk; 5. Patients with ECoG score 0-2; 6. Patients who voluntarily participated and signed informed consent in writing.

Exclusion criteria

Exclusion criteria: 1. Patients who have received systemic chemotherapy after progressing to mcrpc; 2. Patients with chemotherapy contraindications; 3. Patients with contraindications of hormone use.

Design outcomes

Primary

Measure	Time frame
OS;>= grade 3 adverse reaction rate;	—

Secondary

Measure	Time frame
PFS;pain response rate;PSA responserate;	—

Countries

China

Contacts

Public ContactLinjun hu

Cancer Hospital of Huanxing Chaoyang District Beijing

hulinjun_001@163.com+86 15810349445

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026